BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 19337172)

  • 1. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center.
    Gamberini MR; Fortini M; De Sanctis V; Gilli G; Testa MR
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():285-91. PubMed ID: 16462713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
    Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
    Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).
    De Sanctis V; Eleftheriou A; Malaventura C;
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():249-55. PubMed ID: 16462705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran.
    Karamifar H; Shahriari M; Sadjadian N
    East Mediterr Health J; 2003; 9(1-2):55-60. PubMed ID: 15562733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C; Ortega Aramburu JJ; Alonso JL; Albisu M; Casaldáliga J; Díaz de Heredia C; Olivé T; Bastida P
    Med Clin (Barc); 1994 May; 102(19):721-4. PubMed ID: 8041200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival and complications in thalassemia.
    Borgna-Pignatti C; Cappellini MD; De Stefano P; Del Vecchio GC; Forni GL; Gamberini MR; Ghilardi R; Origa R; Piga A; Romeo MA; Zhao H; Cnaan A
    Ann N Y Acad Sci; 2005; 1054():40-7. PubMed ID: 16339650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrinopathies in patients with thalassemias.
    Al-Elq AH; Al-Saeed HH
    Saudi Med J; 2004 Oct; 25(10):1347-51. PubMed ID: 15494799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K; Tzoumari I; Pappa C
    Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases.
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):581-6. PubMed ID: 7634497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine complications in transfusion dependent thalassaemia in Penang Hospital.
    Ong CK; Lim SL; Tan WC; Ong EE; Goh AS
    Med J Malaysia; 2008 Jun; 63(2):109-12. PubMed ID: 18942294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.